https://www.prnewswire.com/apac/news-releases/xtalpi-ai-drug-discovery-collaboration-reaches-milestone-as-pharmaengines-novel-prmt5-inhibitor-pep08-receives-clinical-trial-approvals-302550877.html
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor...
/PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug...
ai drug discovery